Real-World Studies
Perioperative avelumab regimen linked to durable survival in GEA cohort
Alcindor et alInternational Journal of Cancer
Long-term survival data regarding neoadjuvant chemoimmunotherapy in locally advanced gastroesophageal adenocarcinoma (GEA) have historically been limited. A novel study evaluated long-term disease-free survival (DFS) and overall survival (OS) outcomes in 50 patients receiving perioperative aDCF, a regimen combining avelumab with docetaxel, cisplatin, and 5-fluorouracil. The protocol consisted of 4 neoadjuvant cycles of aDCF followed by an en-bloc transthoracic resection and 4 planned adjuvant cycles.
The cohort presented with high baseline clinical disease burden, including 88% (44/50) with cT3 status and 62% (31/50) with node-positive (N+) disease. Overall feasibility was high: 49 of 50 patients (98%) completed neoadjuvant aDCF, and all 50 patients successfully proceeded to surgical resection. Major pathological response (MPR) was achieved in 18% of patients (9/50).
Over a median follow-up period of 71.5 months (range 43–105 months), estimated median DFS was 61.0 months (95% CI not met) and median OS was 77.0 months (95% CI not met). These corresponded to 5-year DFS and OS rates of 50.0% and 60.0%, respectively. In an exploratory analysis of patients with MPR, both 5-year DFS and 5-year OS reached 100%. No new safety signals were observed during the study, supporting aDCF as a feasible regimen conferring durable long-term survival in locally advanced GEA.
Key Takeaways
- At a median follow-up of 71.5 months, perioperative avelumab plus docetaxel, cisplatin, and 5-fluorouracil (aDCF) yielded an estimated 5-year disease-free survival (DFS) of 50.0% (median 61.0 months) and a 5-year overall survival (OS) of 60.0% (median 77.0 months).
- Patients achieving a major pathological response (MPR, 18% [n=9/50]) achieved 100% 5-year DFS and 100% 5-year OS.
- Neoadjuvant aDCF demonstrated feasibility with 98% (49/50) completing neoadjuvant therapy, 100% proceeding to en-bloc resection, and no new safety signals observed.
Read the original sourceInternational Journal of Cancer
